---
title: "Clearmind Medicine releases update on intranasal MEAI formulation retention study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292914059.md"
description: "Clearmind Medicine reported positive ex vivo mucoadhesion results for its intranasal MEAI formulation, demonstrating higher nasal tissue retention compared to a standard solution. These findings support the company's intranasal program for Alcohol Use Disorder, aiming to extend nasal residence time to improve absorption and dosing consistency."
datetime: "2026-07-16T13:30:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292914059.md)
  - [en](https://longbridge.com/en/news/292914059.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292914059.md)
generator: "portal-rs"
---

# Clearmind Medicine releases update on intranasal MEAI formulation retention study

-   Clearmind Medicine reported positive ex vivo mucoadhesion results for an intranasal MEAI formulation, showing higher nasal tissue retention than a standard solution. \* Data support its intranasal program for Alcohol Use Disorder, aiming to extend nasal residence time to improve absorption and dosing consistency. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607160930PRIMZONEFULLFEED9763410) on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CMND.US](https://longbridge.com/en/quote/CMND.US.md)

## Related News & Research

- [Clearmind Medicine sets USD 1 conversion price for USD 696,079.50 in notes into common shares](https://longbridge.com/en/news/297823589.md)
- [Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial](https://longbridge.com/en/news/295833036.md)
- [08:33 ETAKA Foods Launches AKA Studio Alchemy and Opens the Beta for AKA Atlas](https://longbridge.com/en/news/297653338.md)
- [General Mills (GIS) Stock Looks Fairly Priced While Its Broader Checks Look Weak](https://longbridge.com/en/news/297413782.md)
- [11:25 ETOLAY Expands Its Award-Winning Retinol Collection with New Starter Night Repairing Lotion](https://longbridge.com/en/news/297806392.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**